OpenURL Connection Search

Select item for more details and to access through your institution.

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours.
Published in:
British Journal of Cancer, 2012, v. 107, n. 4, p. 604, doi. 10.1038/bjc.2012.319
By:
- Diaz-Padilla, I;
- Siu, L L;
- San Pedro-Salcedo, M;
- Razak, A R A;
- Colevas, A D;
- Shepherd, F A;
- Leighl, N B;
- Neal, J W;
- Thibault, A;
- Liu, L;
- Lisano, J;
- Gao, B;
- Lawson, E B;
- Wakelee, H A
Publication type:
Article
FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL).
Published in:
Hematological Oncology, 2019, v. 37, p. 286, doi. 10.1002/hon.96_2630
By:
- Horwitz, S.M.;
- Scarisbrick, J.;
- Prince, H.M.;
- Whittaker, S.;
- Duvic, M.;
- Kim, Y.H.;
- Quaglino, P.;
- Zinzani, P.L.;
- Bechter, O.;
- Eradat, H.;
- Pinter‐Brown, L.;
- Akilov, O.;
- Geskin, L.;
- Sanches, J.;
- Ortiz‐Romero, P.;
- Lisano, J.;
- Brown, L.;
- Palanca‐Wessels, M.C.;
- Gautam, A.;
- Bunn, V.
Publication type:
Article
FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL).
Published in:
Hematological Oncology, 2019, v. 37, p. 286, doi. 10.1002/hon.96_2630
By:
- Horwitz, S.M.;
- Scarisbrick, J.;
- Prince, H.M.;
- Whittaker, S.;
- Duvic, M.;
- Kim, Y.H.;
- Quaglino, P.;
- Zinzani, P.L.;
- Bechter, O.;
- Eradat, H.;
- Pinter‐Brown, L.;
- Akilov, O.;
- Geskin, L.;
- Sanches, J.;
- Ortiz‐Romero, P.;
- Lisano, J.;
- Brown, L.;
- Palanca‐Wessels, M.C.;
- Gautam, A.;
- Bunn, V.
Publication type:
Article

Found: 3

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours.

FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL).

FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL).